SANUWAVE Health, Inc.

Sanuwave Health, Inc. updated its revenue guidance for the second quarter of 2026 to a range of $8.5 million to $9.5 million, which is below previous expectations. This revision is attributed to significant market disruption impacting Ultramist system sales, including widespread CMS reimbursement clawbacks and the availability of used systems from closing wound care practices. Despite these challenges, the company anticipates record unit sales for applicators in Q2.

SANUWAVE Health, Inc. reported Q1 2026 revenues of $9.6 million, a 3.1% increase year-over-year, marking the highest Q1 revenues in company history. Despite the revenue growth, the company posted a GAAP operating loss of $1.1 million, a significant swing from an operating income of $0.6 million in Q1 2025, and gross margin declined to 77.3%. However, net loss improved to $1.4 million from $6.1 million in the prior year, largely due to non-cash items. The CEO noted a market recovery starting in February and expressed optimism, with the company providing positive revenue guidance for Q2 and reiterating full-year 2026 guidance.

SANUWAVE Health, Inc. reported a net loss of $1.44 million for the first quarter of 2026, a significant improvement from the $6.12 million net loss in Q1 2025. Revenue increased by 3.1% to $9.62 million. The company also restated its Q1 2025 financial statements due to errors in sales tax liabilities and extended warranty revenue recognition, which increased the previously reported net loss for that period. Additionally, SANUWAVE modified its headquarters lease, expanding the property and extending the term.

Sanuwave Health, Inc. reported Q1 2026 revenues of $9.6 million, a 3.1% increase year-over-year, marking its highest Q1 revenue in company history. Despite a GAAP operating loss of $1.1 million and a decrease in gross margin to 77.3%, the company saw a significant improvement in net loss to $1.4 million from $6.1 million in Q1 2025. Management expressed increasing optimism, citing a recovery starting in February, and provided Q2 2026 revenue guidance of $11.1 to $11.6 million, representing a 10-15% increase.

Sanuwave Health, Inc. announced it will host a live conference call on Wednesday, May 13, 2026, at 8:30 AM ET to present its first-quarter 2026 financial results. Investors can access the call via dial-in numbers or a live webcast. A replay of the call will be available until May 27, 2026.

SANUWAVE Health, Inc. will hold its Annual Stockholder Meeting virtually on June 11, 2026. Stockholders will vote on the election of five directors, the ratification of Baker Tilly US, LLP as the independent auditor for 2026, and an advisory vote on executive compensation. The company also detailed its corporate governance, including a new Clawback Policy, and noted some delinquent Section 16(a) reports for 2025.

SANUWAVE Health, Inc. announced preliminary revenues for the first quarter ended March 31, 2026, expecting to be in the range of $9.6 million to $9.7 million. This represents a 3-4% increase year-over-year and is consistent with the company's prior guidance for the quarter.

Sanuwave Health announced preliminary revenues for the first quarter ended March 31, 2026, are expected to be in the range of $9.6 million to $9.7 million. This represents a 3-4% increase over Q1 2025 and is in line with the company's prior guidance. CEO Morgan Frank stated that while some deals shifted out of the quarter, bringing results to the lower end of guidance, the company remains optimistic about its Ultramist product despite market challenges in wound care reimbursement.